Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

RNA Splicing01:32

RNA Splicing

Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
RNA Splicing01:32

RNA Splicing

Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
Alternative RNA Splicing02:18

Alternative RNA Splicing

Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Alternative RNA Splicing02:18

Alternative RNA Splicing

Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Pre-mRNA Processing: RNA Splicing01:32

Pre-mRNA Processing: RNA Splicing

Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeted proteomics for the detection of androgen receptor variants in preclinical models of castration-resistant prostate cancer.

Clinical proteomics·2026
Same author

Case of complete response to immunotherapy in MMR-deficient prostate cancer associated with NK-like and CD4<sup>+</sup>CD8<sup>+</sup> T cells.

Cell reports. Medicine·2026
Same author

3D genome architecture and epigenetic regulation of lineage identity in advanced prostate cancer.

Endocrinology·2026
Same author

Plasma extracellular vesicle proteomics nominates candidate biomarkers of <sup>177</sup>Lu-PSMA-617 outcomes in metastatic prostate cancer patients.

Cell reports. Medicine·2026
Same author

Convergent evolution of complex structural variants drives therapy resistance in metastatic prostate cancer.

Genome biology·2026
Same author

CREB5 regulates stem cell-like transcriptional programs to enhance tumor progression in prostate cancer.

Oncotarget·2026

Related Experiment Video

Updated: May 8, 2026

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

mRNA splicing variants: exploiting modularity to outwit cancer therapy.

Scott M Dehm1

  • 1Department of Laboratory Medicine and Pathology, Masonic Cancer Center, University of Minnesota Twin Cities, Minneapolis, MN 55455, USA. dehm@umn.edu

Cancer Research
|August 24, 2013
PubMed
Summary

Alternative splicing alterations in cancer cells drive therapy resistance by changing protein functions. Understanding these splice variants offers new strategies to resensitize tumors to cancer treatments.

More Related Videos

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells
10:06

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells

Published on: April 26, 2017

Related Experiment Videos

Last Updated: May 8, 2026

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells
10:06

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells

Published on: April 26, 2017

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Cancer therapies target cancer cell vulnerabilities, but resistance limits efficacy.
  • Alternative splicing generates proteome diversity and is often deregulated in cancer.
  • Splicing alterations contribute to primary and acquired resistance to cancer therapies.

Purpose of the Study:

  • To review the role of splice variants in cancer therapy resistance.
  • To discuss mechanisms of splicing deregulation in cancer.
  • To highlight novel strategies for therapy resensitization based on understanding splicing alterations.

Main Methods:

  • Literature review of studies on alternative splicing in cancer.
  • Analysis of identified splicing alterations and their impact on therapy efficacy.
  • Examination of mechanisms driving splicing changes in cancer cells.

Main Results:

  • Splicing alterations can eliminate essential protein domains or enzymatic activities.
  • Aberrant splicing can confer novel signaling functions that bypass cancer therapies.
  • Dysregulated splicing can uncouple signaling pathways from targeted regulatory points.

Conclusions:

  • Splice variants are key drivers of both primary and acquired resistance to cancer therapies.
  • Mechanistic insights into splicing alterations pave the way for developing resensitization strategies.
  • Targeting aberrant splicing presents a promising avenue for improving cancer treatment outcomes.